Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20110229501 | ORGANIC COMPOUNDS The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.... | 09/22/2011 |
| 20110118357 | PROCESS FOR PREPARING O-DESMETHYLVENLAFAXINE The present invention provides a convenient and efficient process for the preparation of O-desmethylvenlafaxine (ODV), comprising the reaction of venlafaxine, or a salt thereof, with a thiol reagent such as a dithiol, an aminothiol or an inorganic thiol. The present inv... | 05/19/2011 |
| 20110077396 | INTERMEDIATES FOR HYDROXYLATED CONTRAST ENHANCEMENT AGENTS In one aspect, the present invention provides a protected ligand precursor having structure XX wherein R8 is independently at each occurrence a protected hydroxy group, a protected C1-C<... | 03/31/2011 |
| 20110015425 | PROCESS The present invention relates to improved processes for the production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein.... | 01/20/2011 |
| 20110009648 | Carbonyl Asymmetric Alkylation This invention relates to processes and intermediates for the stereoselective alkylation of carbonyl groups. The invention in particular allows the stereoselective preparation of the antidepressant drug escitalopram. It has been found that boric or boronic acid derivati... | 01/13/2011 |
| 20100311841 | SYNTHETIC SPHINGOLIPID ANALOGS Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.... | 12/09/2010 |
| 20100191015 | PROCESS FOR THE PREPARATION OF O-DESMETHYLVENLAFAXINE SUCCINATE POLYMORPHIC FORMS The present invention relates to process for the preparation of novel crystalline Desmethylvenlafaxine succinate polymorphic Forms-A, B. The present invention also relates to novel processes for the preparation of 0-Desmethylvenlafaxine succinate polymorphic Forms-(I), ... | 07/29/2010 |
| 20100130736 | METHODS OF CREATING AN INDEX Drug discovery is a complex undertaking facing many challenges, not the least of which is a high attrition rate as many promising candidates prove ineffective or toxic in the clinic owing to a poor understanding of the diseases, and thus the biological systems, they tar... | 05/27/2010 |
| 20100076086 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE The present invention relates to a novel process for the preparation of O-desmethyl venlafaxine (ODV).... | 03/25/2010 |
| 20100068786 | METHODS AND COMPOSITIONS FOR REVERSING P-GLYCOPROTEIN MEDICATED DRUG RESISTANCE A method for inhibiting therapeutic drug resistance within a cell over-expressing a membrane protein is provided. The method comprises synthesizing a dimeric prodrug inhibitor of a monomeric therapeutic agent; administering the dimeric prodrug inhibitor to the membrane ... | 03/18/2010 |
| 20100063160 | POLYMORPHS OF O-DESMETHYL VENLAFAXINE SUCCINATE The present invention relates to crystalline forms of O-desmethyl venlafaxine (ODV) succinate monohydrate, namely Forms I and II, in pure form and to novel processes for their preparation. The present invention provides a process for the preparation of Form II free of F... | 03/11/2010 |
| 20090326075 | ENANTIOMERS OF O-DESMETHYL VENLAFAXINE This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimeth... | 12/31/2009 |
| 20090247472 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS This invention relates to compounds with the formula (I) given below or one of their pharmaceutically acceptable salts, as a medicine; Formula (I) of pharmaceutical compositions comprising one or more compounds with Formula (I) as active constituent, use of compounds wi... | 10/01/2009 |
| 20090240082 | Processes for Preparing Venlafaxine and Venlafaxine Hydrochloride of Form I A process for preparing venlafaxine in a high yield as well as processes for producing venlafaxine hydrochloride of form I having a very hight polymorphic purity are described.... | 09/24/2009 |
| 20090202572 | COMPOSITIONS AND METHODS FOR MODULATING BONE MASS The instant invention relates to compositions and methods for treating or preventing bone diseases. In certain aspects, the invention provides compositions comprising a β-adrenergic antagonist or agonist associated to a bone-targeted molecule, as well as methods of mod... | 08/13/2009 |
| 20090176744 | Deuterated fingolimod This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed... | 07/09/2009 |
| 20090137846 | Processes for the synthesis of O-Desmethylvenlafaxine The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.... | 05/28/2009 |
| 20090137530 | Amine Compound and Use Thereof for Medical Purposes A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition sal... | 05/28/2009 |
| 20080234281 | Mitotic Kinesin Inhibitors The present invention relates to N-substituted benzylic aniline derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositi... | 09/25/2008 |
| 20080161410 | Aminoalkanol Derivatives Disclosed are compounds of formula I wherein R1, R2, R5 and R6 are as defined in the claims; such compounds have interesting pharmacological properties.... | 07/03/2008 |
| 20070287864 | Production Method of Phenylethanolamine Compound, and Its Intermediate A novel production method for a phenylethanolamine compound of the following general formula (III): (wherein R1 represents a hydrogen atom or a halogen atom; R2 represents an alkyl group optionally substituted with an alkoxycarbonyl group... | 12/13/2007 |
| 20070179263 | Functional material comprising fluorine-containing compound There is provided an ionic liquid type functional material which is useful for a lubricant, acid-removing agent, various ionic liquid materials, electrolyte for solar cell and actuator material. The ionic liquid type functional material contains an aromatic compound whi... | 08/02/2007 |
| 20050032848 | Benzamide 2-hydroxy-3-diaminoalkanes The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases c... | 02/10/2005 |
